"Azabicyclo Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS.
Descriptor ID |
D053961
|
MeSH Number(s) |
D02.145.074 D03.605.084.500
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azabicyclo Compounds".
Below are MeSH descriptors whose meaning is more specific than "Azabicyclo Compounds".
This graph shows the total number of publications written about "Azabicyclo Compounds" by people in this website by year, and whether "Azabicyclo Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2010 | 2 | 0 | 2 |
2015 | 1 | 0 | 1 |
2016 | 4 | 0 | 4 |
2017 | 3 | 0 | 3 |
2018 | 8 | 1 | 9 |
2019 | 5 | 1 | 6 |
2020 | 2 | 1 | 3 |
2021 | 2 | 4 | 6 |
2022 | 0 | 3 | 3 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azabicyclo Compounds" by people in Profiles.
-
Karlowsky JA, Hackel MA, Stone GG, Sahm DF. In Vitro Activity of Ceftibuten-Avibactam against ?-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0134622.
-
Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM, Cusick SM, Pevear DC, Moeck G, Sahm DF. In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0128122.
-
Karlowsky JA, Wise MG, Hackel MA, Pevear DC, Moeck G, Sahm DF. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-?-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018-2020 Global Surveillance Collection. Antimicrob Agents Chemother. 2022 11 15; 66(11):e0093422.
-
Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022 05 17; 66(5):e0018922.
-
Karlowsky JA, Kazmierczak KM, Valente MLNF, Luengas EL, Baudrit M, Quintana A, Irani P, Stone GG, Sahm DF. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019. Braz J Infect Dis. 2021 Nov-Dec; 25(6):101647.
-
Karlowsky JA, Hackel MA, Sahm DF. In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales. Antimicrob Agents Chemother. 2022 01 18; 66(1):e0130421.
-
Karlowsky JA, Lob SH, Raddatz J, DePestel DD, Young K, Motyl MR, Sahm DF. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017. Clin Infect Dis. 2021 06 15; 72(12):2112-2120.
-
Lob SH, Hackel MA, Young K, Motyl MR, Sahm DF. Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019. Diagn Microbiol Infect Dis. 2021 Aug; 100(4):115421.
-
Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015-2017. J Pediatric Infect Dis Soc. 2021 Apr 03; 10(3):274-281.
-
Estabrook M, Kazmierczak KM, Wise M, Arhin FF, Stone GG, Sahm DF. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017. J Glob Antimicrob Resist. 2021 03; 24:316-320.